Navigating the IND (Investigational New Drug) submission process can be challenging. Our comprehensive webinar, "Is Your Drug Ready for an IND?" is designed to provide you with the knowledge and tools necessary to streamline this crucial step in drug development.
What you will learn:
Listen to industry experts as they delve into the essential components of the IND enabling process. This webinar covers:
Tina Rogers, Ph.D., DABT, M.B.A.
Senior Technical Director, Toxicology
Dr. Rogers is an expert in preclinical drug development services. Her leadership positions include vice president of preclinical sciences at Altasciences (formerly SNBL USA), executive vice president and director of research at M.P.I. Research (now Charles River), and vice president of drug development at Southern Research Institute. She has served as an advisor and driven growth and profitability in all of her leadership roles.
Dr. Rogers holds a doctoral degree in molecular and cellular biology and pathobiology from the Medical University of South Carolina and an M.B.A. from Auburn University. She has a broad technical background, including cell biology, immunology, toxicology, cell and gene therapy, sepsis, inflammation, BL-3 and select agents, flow cytometry and predictive/in vitro toxicology. Dr. Rogers also serves as a board member for several biotech, academic and not-for-profit institutions and is a Diplomate of the American Board of Toxicology (DABT).